TaiMed Biologics (Ticker: 4147.TWO) today announced that it has entered into a Post-Approval Named Patient Program (PA-NPP) Supply Agreement with R-Pharm, JSC, a leading Russian pharmaceutical company. Under this agreement, R-Pharm is authorized to provide Trogarzo® (ibalizumab-uiyk) to eligible individual patients with multidrug-resistant HIV-1 infection in Russia and related territories, in accordance with local regulatory authorities and applicable laws.
This program enables early access to Trogarzo® for patients with urgent medical needs prior to the product’s formal market approval in Russia.
“We are honored to collaborate with R-Pharm to expand access to Trogarzo® for patients who have exhausted other treatment options,” said Dr. Jimmy Chang, Chief Executive Officer of TaiMed Biologics. “This partnership reinforces our commitment to addressing unmet medical needs in multidrug-resistant HIV and marks another milestone in TaiMed’s global expansion.”
Vasiliy Ignatiev, Chief Executive Officer of R-Pharm, commented: “There remains a significant need for treatments for patients with multidrug-resistant HIV infection, for whom existing treatment regimens fail to suppress the virus. Until now, their only optionswere participation in clinical trials or transition to palliative care. Now, thanks to an agreement with TaiMed Biologics, we will be able to offer them a new drug and new hope for a full life.”

About TaiMed Biologics
TaiMed Biologics (TPEX: 4147) is a biotechnology company headquartered in Taiwan with operations in the United States. Founded in 2007, TaiMed achieved a historic milestone as the first Taiwanese company to develop a biologic drug, receiving US FDA approval and advancing to global commercialization. The Company is dedicated to addressing unmet medical needs in infectious diseases and autoimmune disorders through its proprietary monoclonal antibody and ADC platforms. Its pipeline includes Trogarzo®, the long-acting antibody combination TMB-365/TMB-380, and a next-generation CD4-targeted TMB-365-ADC platform.
Beyond its innovative drug pipeline, TaiMed operates a rapidly growing Contract Development and Manufacturing Organization (CDMO) business. The Company offers end-to-end biologics manufacturing solutions—from process development and analytical testing to commercial-scale cGMP production. With state-of-the-art facilities in Taiwan, TaiMed’s CDMO division supports global partners in accelerating their biologics to market.

About R-Pharm
R-Pharm,JSC is a leading Russian pharmaceutical company headquartered in Moscow, specializing in the research, development, manufacturing, and distribution of innovative medicines across the Eurasian region. R-Pharm's mission is to increase the accessibility of advanced diagnostics, preventative care and therapy methods in Russia and abroad. The group has signed agreements on strategic partnership, production localization and technology transfer with the world's leading manufacturers of pharmaceuticals and medical equipment. The most important activities of the group include research and development.
Today, R-Pharm’s research pipeline contains more than 100 knowledge-intensive products, many of which make a serious contribution to the fight against high burden diseases. Following corporate social responsibility policies, R-Pharm organizes projects aiming to increase awareness about dangerous diseases, promote healthy lifestyle, improve the educational system and foster a new generation of professionals.